Advanced Search


Study ID Status Title Patient Level Data
VEG109603 Completed A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics dose escalation of Pazopanib in Combination with Epirubicin or Doxorubicin for Advanced Solid Tumors
VEG109607 Completed A Phase I Study of Pazopanib in Combination with Either Erlotinib or Pemetrexed in Patients with Advanced Solid Tumors
VEG110190 Completed A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors
VEG110727 Completed A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
VEG20002 Completed Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma
VEG20006 Completed A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients with Relapsed or Refractory Multiple Myeloma
VEG20007 Completed A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
VIA-001 Completed Cost-effectiveness of a combination of Fluticasone Propionate and Salmeterol Xinafoate in comparison with conventional therapies of bronchial asthma (VIANI Real life).
VIA-002 Completed Viani® forte Discus® Post Marketing Surveillance Study.
VIN10003 Completed The Phase I Absolute Bioavailability Study of Oral NAVELBINE (vinorelbine tartrate) in Patients with Solid Tumors.
VIN10004 Completed An Open-Label Study to Provide Continuing Treatment with NAVELBINE (vinorelbine tartrate) Soft Gelatin Capsules or Injection to Subjects with Solid Tumors.
VINA1001 Completed A Phase I, Open-Label, Randomized, Crossover Study of Oral and Intravenous NAVELBINE (vinorelbine tartrate) in Subjects with Malignant Solid Tumors and Varying Degrees of Hepatic Function.
VINA2004 Completed A Phase II, Open-Label, Prospective, Randomized, Controlled, Multicenter Study of Single Agent NAVELBINE (vinorelbine tartrate) Administered Orally or Administered Intravenously for the Treatment of Chemotherapy-Naïve Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy- Na ...
VLX103596 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection. Study Listed on
VLX105832 Completed The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection Study Listed on
VRA105345 Completed A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth extraction
VRA107438 Terminated A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.
VRX-RET-E22-101 Completed Single-Dose Pharmacokinetics of Retigabine in Healthy Subjects and Patients with Various Degrees of Renal Insufficiency Study Listed on
VRX-RET-E22-101SR Completed Open-Label, Single-Dose, 8-Period Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a 400 mg Dose of Retigabine Sustained-Release Formulations in Seven Dosing Periods Versus a 200 mg Dose of Retigabine Immediate-Release Formulation in One Dosing Period in Healthy Adult Male Subjects Study Listed on
VRX-RET-E22-102 Completed Single-Dose Pharmacokinetics Study of Retigabine in Patients with Various Degrees of Hepatic Impairment Study Listed on
VRX-RET-E22-103 Completed A Double-Blind Randomized Parallel-group Trial to Define the ECG Effects of Retigabine Using a Maximum Tolerated Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial Study Listed on
VRX-RET-E22-104 Completed Comparative, Randomized, Open-Label, Single-Dose, 2-way Crossover Food Effect, Safety and Tolerability Study of a 400-mg Dose of the Retigabine Market Image Tablet in Healthy Adult Male Subjects Study Listed on
VRX-RET-E22-105 Completed Comparative, Randomized, Open-Label, Single-Dose, 2-Way Crossover Bioavailability, Safety and Tolerability Study of a 400mg Dose of Retigabine Administered as the Clinical Trials Formulation and the Market Image Formulation in Healthy Adult Male Subjects Study Listed on
VRX-RET-E22-106 Completed A Pharmacokinetic Interaction Study Evaluating the Effect of Repeated Retigabine Dosing on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Volunteers Study Listed on
VRX-RET-E22-107 Completed A Randomized, Partially Double-Blind, Four-Way Crossover Study to Determine the Effects of a Single Dose of Retigabine Combined with a Single Dose of Alcohol Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.